Daiichi Sankyo's global head of R&D talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square
From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond HER2 and TROP2, plus what the company is looking at outside of ADCs.